We have expertise working with elongation translation by studying eElongation Factor-2 (eEF2) in the aging and oxidative stress conditions https://pubmed.ncbi.nlm.nih.gov/33425211/, and now we have some preliminary results showing a potential new mechanism of eEF2 in cancer. In fact, overexpression of eEF2 has been reported in several cancer types, and depletion of eEF2 with shRNA decrease the growth of cancer cell lines.
Due to, so far, very few specific translation elongation-inhibitors targeting eEF2 are available, for example:
- Bouvardin (NSC 259968) https://pubchem.ncbi.nlm.nih.gov/compound/429598
- Myclamide B https://pubchem.ncbi.nlm.nih.gov/compound/Mycalamide-B
- Meta Br-N-29-H derivative of RA-VII (PubChem CID: 3034401) https://pubchem.ncbi.nlm.nih.gov/compound/3034401
We are currently looking for a collaboration within our project for providing some of these compounds.
Happy to discuss further
Prof. Sandro Argüelles, PhD [email protected]
Department of Physiology, Faculty of Pharmacy & Biology, University of Seville |Seville, Spain |
COLLABORATION CALL: MOLECULAR MECHANISM LINKED WITH THE INHIBITION OF eEF2 IN CANCER. https://t.co/EEKAilggQ7 #INPST #DrugDiscovery
CC: @erlesen @HealthyFellow @MarcoAlbuja @ShraboniGhosal @nathantwala @anjbth @JJ_Angelus @PepperPell @el_ronan @JoyitaB @krkharat @Nwauka pic.twitter.com/2x0ITjOrZN
— International Natural Product Sciences Taskforce (@_INPST) October 24, 2021